Clinical Research

Genexine's GX-E4 Phase 3 trial shows non-inferiority to Mircera for anemia treatment, presented at WCN2023

Kidneys are responsible for 90% of the EPO produced in our bodies. CKD-induced anemia is caused by the failure to produce EPO (erythropoietin) due to long-...

 April 12, 2023 | News

OrganaBio Delivers RUO & GMP LeukoPAC™ Collections to Singapore

The monoclonal antibodies (mAbs) daratumumab, and elotuzumab have been approved by the U.S. Food and Drug Administration for treating multiple myeloma (MM)...

 April 10, 2023 | News

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

Developed with site specific conjugate technology, 9MW2821 is China's first, global second Nectin-4 targeted ADC approved for clinical study. The...

 April 08, 2023 | News

WuXi STA Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System

 WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a lar...

 April 06, 2023 | News

Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio

Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, said, " By combining our respective expertise in antibody engineering and the disease area, we a...

 April 06, 2023 | News

Standigm, Institut Pasteur Korea identify drug candidates for drug-resistant TB with grant

 Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, and Korean non profit research institute Instit...

 April 05, 2023 | News

Indivumed becomes Indivumed Therapeutics to advance Precision Oncology with Data and AI

After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acqui...

 April 05, 2023 | News

RVAC Medicines announces research collaboration with University of Pennsylvania mRNA Vaccine Pioneer

Autoimmune diseases occur when the body's immune system becomes oversensitive to proteins that are normally harmless, thus triggering a reaction that leads...

 April 03, 2023 | News

Remedium and Exothera partner on scale-up and demonstration runs for AAV2-FGF18

Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18. OA is the larges...

 March 30, 2023 | News

Thermo Fisher Scientific and Arsenal Biosciences Collaborate for T-Cell Therapy Manufacturing

ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...

 March 29, 2023 | News

Noul Co. Ltd's The RIGHT Foundation Begins Research and Development to Aid Malaria Control

Noul Co. Ltd (CEO : David Lim) announced that it has signed an agreement with The RIGHT Foundation to conduct a global clinical studies to determine t...

 March 28, 2023 | News

Phase 1 trial of OLX72021of Treatment of Androgenic Alopecia has been approved for initiation in Australia

OliX will evaluate the safety and tolerability of OLX72021 in Phase 1 clinical trial Excellent hair growth effect is observed when used as external solu...

 March 27, 2023 | News

Enveric Biosciences Selects Australian CRO, Avance Clinical

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of nove...

 March 27, 2023 | News

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has received r...

 March 27, 2023 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close